PA8496001A1 - Polimorfos de un citrato de azobiciclo [2.2.2] oct-3-ilamina cristalino y sus composiciones farmaceuticas - Google Patents
Polimorfos de un citrato de azobiciclo [2.2.2] oct-3-ilamina cristalino y sus composiciones farmaceuticasInfo
- Publication number
- PA8496001A1 PA8496001A1 PA20008496001A PA8496001A PA8496001A1 PA 8496001 A1 PA8496001 A1 PA 8496001A1 PA 20008496001 A PA20008496001 A PA 20008496001A PA 8496001 A PA8496001 A PA 8496001A PA 8496001 A1 PA8496001 A1 PA 8496001A1
- Authority
- PA
- Panama
- Prior art keywords
- polymorphes
- oct
- citrate
- crystalline
- azobiciclo
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title 1
- AKQZEFRALAUBFS-UHFFFAOYSA-N ilamine Natural products COC(C)C(O)(C(=O)OCC1=CCN2CCCC12)C(C)(C)O AKQZEFRALAUBFS-UHFFFAOYSA-N 0.000 title 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
DOS FORMAS POLIMORFICAS CRISTALINAS DE CITRATO DE (2-BENZHIDRIL-1-AZO-BICICLO[2.2.2] OCT-3-IL)-(5-ISOPROPIL-2-METOXIBENCIL) AMINA MONOHIDRATO (LOS MONOHIDRATOS) SON LA FORMA A Y LA FORMA B. LA COMPOSICION FARMACEUTICA QUE CONTIENE AL MENOS UNO DE ESTOS POLIMORFOS TIENE UNA ESTABILIDAD VENTAJOSA PARA LA FORMULACION PARA EL TRATAMIENTO DE EMESIS AGUDA EN PACIENTES QUE RECIBEN QUIMIOTERAPIA. LA ADMINISTRACION DE ESTA COMPOSICION FARMACEUTICA ES CONVENCIONALMENTE ORAL, MEDIANTE PREFERIBLEMENTE COMPRIMIDOS O CAPSULAS, E INTRAVENOSA. SE DESCRIBE TAMBIEN UN PROCEDIMIENTO DE OBTENCION DE LAS FORMAS A Y B.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13699599P | 1999-06-01 | 1999-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8496001A1 true PA8496001A1 (es) | 2002-07-30 |
Family
ID=22475353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20008496001A PA8496001A1 (es) | 1999-06-01 | 2000-05-19 | Polimorfos de un citrato de azobiciclo [2.2.2] oct-3-ilamina cristalino y sus composiciones farmaceuticas |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6387925B1 (es) |
| EP (1) | EP1181289A1 (es) |
| JP (1) | JP2003501353A (es) |
| KR (1) | KR20020005055A (es) |
| CN (1) | CN1353712A (es) |
| AP (1) | AP2001002350A0 (es) |
| AR (1) | AR029753A1 (es) |
| AU (1) | AU767331B2 (es) |
| BG (1) | BG106139A (es) |
| BR (1) | BR0011125A (es) |
| CA (1) | CA2372236A1 (es) |
| CO (1) | CO5170468A1 (es) |
| CR (1) | CR6513A (es) |
| CZ (1) | CZ20014270A3 (es) |
| DZ (1) | DZ3051A1 (es) |
| EA (1) | EA004206B1 (es) |
| EE (1) | EE200100655A (es) |
| GT (1) | GT200000086A (es) |
| HK (1) | HK1046407A1 (es) |
| HN (1) | HN2000000076A (es) |
| HR (1) | HRP20010884A2 (es) |
| HU (1) | HUP0201798A3 (es) |
| IL (1) | IL145952A0 (es) |
| IS (1) | IS6129A (es) |
| MX (1) | MXPA01012328A (es) |
| NO (1) | NO20015845L (es) |
| NZ (1) | NZ514762A (es) |
| OA (1) | OA11955A (es) |
| PA (1) | PA8496001A1 (es) |
| PE (1) | PE20010155A1 (es) |
| PL (1) | PL352715A1 (es) |
| SK (1) | SK17342001A3 (es) |
| SV (1) | SV2002000092A (es) |
| TN (1) | TNSN00119A1 (es) |
| TR (1) | TR200103472T2 (es) |
| UY (1) | UY26177A1 (es) |
| WO (1) | WO2000073303A1 (es) |
| ZA (1) | ZA200109839B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1551846A1 (en) * | 2002-10-04 | 2005-07-13 | Merck Sharp & Dohme Ltd. | Azabicyclic spiroether derivatives as receptor antagonists |
| CA2610633A1 (en) * | 2003-06-18 | 2004-12-29 | Teva Pharmaceutical Industries Ltd | Fluvastatin sodium crystal form lxxix, processes for preparing, compositions and methods of using |
| US7371906B2 (en) | 2004-08-24 | 2008-05-13 | Eastman Kodak Company | Process for photo-oxidative stability improvements |
| US9446029B2 (en) | 2010-07-27 | 2016-09-20 | Colorado State University Research Foundation | Use of NK-1 receptor antagonists in management of visceral pain |
| CN110577522B (zh) * | 2018-06-07 | 2022-12-27 | 东莞市东阳光动物保健药品有限公司 | 马罗匹坦柠檬酸盐新晶型及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005525A1 (en) * | 1988-11-23 | 1990-05-31 | Pfizer Inc. | Quinuclidine derivatives as substance p antagonists |
| PL171379B1 (en) * | 1991-05-31 | 1997-04-30 | Pfizer | Method of obtaining novel derivatives of quinuclidine |
| NZ254604A (en) * | 1992-11-12 | 1997-06-24 | Pfizer | Quinuclidine derivative and pharmaceutical compositions thereof |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| US6262067B1 (en) * | 1999-06-22 | 2001-07-17 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions |
-
2000
- 2000-05-12 US US09/887,682 patent/US6387925B1/en not_active Expired - Fee Related
- 2000-05-17 EA EA200100982A patent/EA004206B1/ru not_active IP Right Cessation
- 2000-05-17 NZ NZ514762A patent/NZ514762A/xx unknown
- 2000-05-17 CN CN00808340A patent/CN1353712A/zh active Pending
- 2000-05-17 HU HU0201798A patent/HUP0201798A3/hu unknown
- 2000-05-17 CA CA002372236A patent/CA2372236A1/en not_active Abandoned
- 2000-05-17 TR TR2001/03472T patent/TR200103472T2/xx unknown
- 2000-05-17 SK SK1734-2001A patent/SK17342001A3/sk unknown
- 2000-05-17 HN HN2000000076A patent/HN2000000076A/es unknown
- 2000-05-17 CZ CZ20014270A patent/CZ20014270A3/cs unknown
- 2000-05-17 WO PCT/IB2000/000663 patent/WO2000073303A1/en not_active Application Discontinuation
- 2000-05-17 OA OA1200100317A patent/OA11955A/en unknown
- 2000-05-17 IL IL14595200A patent/IL145952A0/xx unknown
- 2000-05-17 AP APAP/P/2001/002350A patent/AP2001002350A0/en unknown
- 2000-05-17 MX MXPA01012328A patent/MXPA01012328A/es not_active Application Discontinuation
- 2000-05-17 EE EEP200100655A patent/EE200100655A/xx unknown
- 2000-05-17 JP JP2001500628A patent/JP2003501353A/ja active Pending
- 2000-05-17 KR KR1020017015324A patent/KR20020005055A/ko not_active Application Discontinuation
- 2000-05-17 PL PL00352715A patent/PL352715A1/xx not_active Application Discontinuation
- 2000-05-17 AU AU44246/00A patent/AU767331B2/en not_active Ceased
- 2000-05-17 EP EP00925526A patent/EP1181289A1/en not_active Withdrawn
- 2000-05-17 BR BR0011125-2A patent/BR0011125A/pt not_active IP Right Cessation
- 2000-05-19 PA PA20008496001A patent/PA8496001A1/es unknown
- 2000-05-26 CO CO00039192A patent/CO5170468A1/es not_active Application Discontinuation
- 2000-05-29 UY UY26177A patent/UY26177A1/es not_active Application Discontinuation
- 2000-05-30 AR ARP000102664A patent/AR029753A1/es unknown
- 2000-05-30 PE PE2000000517A patent/PE20010155A1/es not_active Application Discontinuation
- 2000-05-30 GT GT200000086A patent/GT200000086A/es unknown
- 2000-05-31 SV SV2000000092A patent/SV2002000092A/es unknown
- 2000-05-31 DZ DZ000102A patent/DZ3051A1/xx active
- 2000-05-31 TN TNTNSN00119A patent/TNSN00119A1/fr unknown
-
2001
- 2001-10-26 IS IS6129A patent/IS6129A/is unknown
- 2001-11-23 BG BG106139A patent/BG106139A/bg unknown
- 2001-11-27 CR CR6513A patent/CR6513A/es not_active Application Discontinuation
- 2001-11-27 HR HR20010884A patent/HRP20010884A2/hr not_active Application Discontinuation
- 2001-11-29 ZA ZA200109839A patent/ZA200109839B/xx unknown
- 2001-11-30 NO NO20015845A patent/NO20015845L/no not_active Application Discontinuation
-
2002
- 2002-10-30 HK HK02107840.5A patent/HK1046407A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR023423A1 (es) | Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos | |
| CL2009001682A1 (es) | Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00). | |
| ECSP055738A (es) | PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL | |
| DE69931930D1 (de) | Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen | |
| AR023228A1 (es) | Composiciones en espuma estables | |
| CL2009001279A1 (es) | Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03). | |
| EE04799B1 (et) | Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid | |
| EE9900441A (et) | Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nende solvaatide suu kaudu manustamiseks | |
| BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
| DE60038183D1 (de) | Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe | |
| NO20100302L (no) | Sammensetninger som inneholder organiske forbindelser | |
| AR066982A2 (es) | Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos | |
| AR025959A1 (es) | DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
| ES2144192T3 (es) | Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| BR0015605A (pt) | Composição e uso | |
| AR018197A1 (es) | Compuestos de piperidina, un procedimiento para su preparacion, una composicion y uso del mismo para la preparacion de un medicamento | |
| AR021355A1 (es) | Derivados de quinolina. procedimiento para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de unmedicamento | |
| AR013079A1 (es) | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios | |
| AR027360A1 (es) | Composicion farmaceutica | |
| MX9300399A (es) | Derivados heterotriciclicos. | |
| ATE215817T1 (de) | Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis | |
| PA8496701A1 (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo [2.2.2] oct- 3 - ilamina y sus composiciones farmaceuticas | |
| CO5540294A2 (es) | Una combinacion de un derivado de rapamicina y un agente alquilante seleccionado de ciclofosfamida y carmustina y composiciones que las contienen | |
| PA8496001A1 (es) | Polimorfos de un citrato de azobiciclo [2.2.2] oct-3-ilamina cristalino y sus composiciones farmaceuticas | |
| HUP0200055A2 (hu) | 16-Hidroxi-ösztratriének és ezeket tartalmazó gyógyszerkészítmények |